Hutchmed (china) Share Discussion Threads

[mcmather] 30/6/2021 10:48

Thanks; quick reminder to myself to press the 'refresh page' button!

[lauders] 30/6/2021 10:34

No. Nearly HK$60. It gave some back at the end.

[mcmather] 30/6/2021 10:31

Bit of a 'cloudy' head this morning; just to make sure I'm not missing something obvious, did this close in HK at HK$82.850?

[steeplejack] 30/6/2021 08:45

You might be right.After a long delay in the HK listing,it was probably decided that it would be propitious to list on the Hong Kong market now given the news pipeline.The AIM market quote here will prove to be pretty ineffectual in reflecting whats happening in HK.We'll have to wait for the Nasdaq to open to see just how things settle down.

[its the oxman] 30/6/2021 08:43

Took a few profits over 600p but mainly holding on, longer term more news and more upside. Great to see a positive move though.

[nerdofsteel] 30/6/2021 08:41

I've been saying for the last couple of years that in order to get a proper valuation equivalent to its peers the AIM & NASDAQ listings are a waste of time, an Asian listing is what was needed. I don't anticipate it dropping much from here but should increase as revs ramp up and the Company becomes profitable in 2 or 3 years time.

[lauders] 30/6/2021 08:29

Imagine if they now follow the listing up with some decent news! That would really be something. We have news due, so perhaps something re: developments in the US would be next? If they seize the opportunity we could see yet more strength. Would the timing of the HKEX listing in anyway be dependent on some upcoming news?

[nerdofsteel] 30/6/2021 08:20

at last the Company gets a proper forward looking valuation equivalent to Beigene, Innovent etc

[nerdofsteel] 30/6/2021 07:02

This is a great opening, currently now $78 (around £7.00). I have been hoping for a long time that the Company would list in HK and the listing would be well received. At last it seems our valuation may become more aligned with other companies of a similar type and size.

Now we can get to valuation multiples enjoyed by Innovent & Beigene.

[cockneytrader] 30/6/2021 07:01

Hong Kong is still open and the price is now 73.5 hkd or 6.83 per share. Happy days.

[sportii] 30/6/2021 03:48

13.5 million shares traded with in the first two hours of trading! Clearly a sign of interest among Asian investors.
SP at 56.3 HKD which makes AIM listed HCM share price £5.20 (approximately).
Company website yet to show 13.hk price.

[cockneytrader] 30/6/2021 02:41

Excellent ceremony, and 13 stock code is lucky for patients and investors. An exciting journey ahead. 55 HKD as I type.

[lauders] 30/6/2021 02:33

Up 30% currently at the very start. Let's see how it pans out over the weeks and years ahead. GLA!

Edit - Worth sharing this link too:

[lauders] 30/6/2021 01:01

Thanks NofS. Being "local" I will also be attending. Appreciate the link :-)

[nerdofsteel] 29/6/2021 16:29

Join us for the live streaming of HUTCHMED's HKEX Listing Ceremony on 30 Jun 9am HKT ( 9pm EDT, 29 Jun ) ! We will trade under the stock code "13" in Hong Kong



I'll certainly be there!!

[nerdofsteel] 25/6/2021 07:38

I agree, they should move to a Main Listing. It is not always plain sailing however as many Co's that have done it have found no advantage although with Hutchmed's mcap it would be in the FTSE250 and could end up in the FTSE100 soon.

But I think that opening the Co. up to Chinese and HK investors will prove to be very positive. I expect a STAR Market listing to follow very quickly from this listing.

[sportii] 23/6/2021 20:07

Nofs, HCM’s AIM listing status has been discussed a number of times on this message board. Management’s reaction has always been a ‘no reaction’.

Another matter which should not be forgotten is the fact that most of the major institutional investors who have invested chunks of 100 million USD at different times over the last couple of years have been issued AIM listed shares (and not ADRs. Please correct if I am wrong). There must be some technical reasons for doing so. We have seen few posts suggesting closing down AIM listing as it isn’t worth maintaining AIM listing because of the small number of shares traded per day, My query is; if the major share holders (as well as many of the directors) are holding LSE AIM listed HCM shares, how practical it is to contemplate closing the AIM listing.
Perhaps, a better alternative is moving to the main LSE. The very obvious advantage of doing so has been mentioned quoting examples of few other stocks. Hutcmed truly deserves a much better status at the LSE following all the good news of the last two weeks, in particular.
Let’s hope the CEO will seriously think about it. Let it be a win-win situation for all.

[cockneytrader] 23/6/2021 18:49

This is the sort of nonsense that will lead many companies down the private equity route. The public markets have become casinos. They are no longer fit for purpose.

[dbadvn] 23/6/2021 16:26

Draper Esprit spell it out for them (as we both have many times)

“ The Company directors believe that Admission will further enhance the Company's profile and brand recognition with investee companies, extend the Company's shareholder base to a wider group of institutional investors, assist in the recruitment, retention and incentivisation of all employees; and support the Company's growth strategy.”

Even more to the point a lot of the pension funds and IT’s will be constrained from buying because of the AIM listing. It’s not rocket science ( a lot easier than Bioscience ) . Ch should just get on with it. No excuses now.

[steeplejack] 23/6/2021 16:25

The final offer price for both the International Offering and the Hong Kong Public Offering (the "Offer Price") has been set at HK$40.10 per Share, which is equivalent to approximately US$25.82 per American depositary share ("ADS") or GBP3.70 per Share....and now the price is up around 430p.The market operators have had their way here and the company has received that much less from the placing.However,onwards and upwards.

[nerdofsteel] 23/6/2021 15:22

I've raised the subject of a Main Listing at a number of AGM's but the Company says they see no material benefit to moving from AIM. I suspect they originally thought NASDAQ would effectively be their primary listing, even though it's just an adr program, and now they think the Asian listing will be considered the main or primary listing. Let's hope they are right.

[steeplejack] 23/6/2021 13:13

Draper Esprit ....Todays RNS.What do they know that HutchMed refuse to accept!The Company directors believe that the Company is now of a size and scale to justify its migration from the AIM market of the London Stock Exchange ("AIM") and the Euronext Growth Market to the Main Markets. The Company has a proven track record and an ambitious asset management strategy focused on accelerating its support to UK and European high-growth technology businesses in need of longer term investment which the Company is able to provide via its balance sheet and a growing base of third party funds. The Company directors believe that Admission will further enhance the Company's profile and brand recognition with investee companies, extend the Company's shareholder base to a wider group of institutional investors, assist in the recruitment, retention and incentivisation of all employees; and support the Company's growth strategy.

[steeplejack] 23/6/2021 08:57

It's been a chequered ride being a shareholder here and i think it owes something to the company's attitude to equity markets in general.On its website,for example,it waxes lyrical about the merits of the AIM market as if its something comparable to the Nasdaq market.We all know that an AIM listing has implicit drawbacks.(Look at Draper Esprit today which is to leave the AIM market for a full listing.Draper shares are up 7.5% today alone).HZM has had a dispiritingly erratic approach to placings over the years,deferred plans for an HK listing,rushed US issues,unanticipated parent company decisions to partially divest.There is little doubt that the company's approach to corporate affairs has compromised its stockmarket rating.I am hoping that this HK listing might herald a new chapter.

[nerdofsteel] 23/6/2021 08:35

well I have what I wanted. Savo approval in China, an Asian listing, the second Surufatinib approval in China, Surufatinib NDA going thru the FDA rolling approval, great Q1 results and more, and yet we are at the same mcap we were at 4 years ago. I hope this is the start of a new era for the company and a journey towards the $20bn mcap I think they can achieve in the next 5 years.